Brain Neoplasms
FDA Grants Accelerated Approval to Jazz’s Dordaviprone (Modeyso), the First Treatment for Ultra-Rare Brain Tumor
Dordaviprone; Modeyso; FDA approval; H3 K27M-mutant diffuse midline glioma; ultra-rare brain tumor; Jazz Pharmaceuticals; accelerated approval; pediatric brain cancer; Chimerix acquisition; confirmatory trial
Jazz Pharmaceuticals to Acquire Chimerix for $935 Million, Gaining Promising Brain Tumor Drug Dordaviprone
Jazz Pharmaceuticals, Chimerix, Acquisition, Dordaviprone, Brain tumor, H3 K27M-mutant diffuse glioma, FDA approval, Oncology pipeline
Merck Acquires “Chameleon” Approach to Combat Deadly Brain Cancers for $30 Million
Merck, brain cancer, chameleon approach, $30 million, pharmaceutical acquisition
FDA Approves Servier’s Brain Cancer Drug, Triggering $1 Billion Payout for Agios
FDA approval, Servier, brain cancer drug, Voranigo, Agios Pharmaceuticals, IDH1 and IDH2 mutations, blood-brain barrier, cancer metabolism, royalty payments
FDA Approves Voranigo, the First Targeted Therapy for Grade 2 IDH-Mutant Glioma
Voranigo, FDA approval, targeted therapy, Grade 2 IDH-mutant glioma, brain tumor, Servier Pharmaceuticals, IDH1/IDH2 inhibitor
FDA Fast-Tracks Day One’s Innovative Therapy for Pediatric Brain Tumors
FDA, accelerated approval, Day One, targeted treatment, pediatric brain tumors, glioma, children, cancer treatment, innovative therapy.
Day One Outshines Novartis: FDA Approves Ojemda for Wider Pediatric Brain Tumor Treatment
Day One, Novartis, FDA, Ojemda, pediatric brain tumor, cancer treatment, clinical trials, pharmaceutical industry.